Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Borko D Jovanovic

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Neoplasia (New York, N.Y.)|June 22, 2005
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic miceRene Hennig, Jacinthe Ventura, Ralf Segersvard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic statusCharles L Bennett, Douglas K Price, Simon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin LymphomaAndrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion ProductNeelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Clinical and Translational Science|September 13, 2014
Assessing statistical competencies in clinical and translational science education: one size does not fit allRobert A Oster, Christopher J Lindsell, Leah J Welty, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2003
Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancerChris H Takimoto, Kira Glover, Xiaoke Huang, et al.
Oral Oncology|July 13, 2013
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakiaStuart J Wong, Bruce Campbell, Becky Massey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trialSeema A Khan, Robert T Chatterton, Nancy Michel, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Neoplasia (New York, N.Y.)|June 22, 2005
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic miceRene Hennig, Jacinthe Ventura, Ralf Segersvard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic statusCharles L Bennett, Douglas K Price, Simon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin LymphomaAndrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion ProductNeelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Clinical and Translational Science|September 13, 2014
Assessing statistical competencies in clinical and translational science education: one size does not fit allRobert A Oster, Christopher J Lindsell, Leah J Welty, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2003
Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancerChris H Takimoto, Kira Glover, Xiaoke Huang, et al.
Oral Oncology|July 13, 2013
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakiaStuart J Wong, Bruce Campbell, Becky Massey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trialSeema A Khan, Robert T Chatterton, Nancy Michel, et al.
Pageof 3